Device Trial Radar · NCT03557892
Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Apr 1, 2018
Primary completion
Dec 20, 2019
Study completion Jan 2, 2020
Sponsor
- Lead sponsor
- Azienda Ospedaliero-Universitaria CareggiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 15, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Several studies have shown that Continuous Subcutaneous Insulin Infusion together with Continuous Glucose Monitoring improves glycemic control in type 1 diabetes when compared to more traditional approaches; however, in available trials the basal insulin used in multi-injection therapy is typically glargine, which is associated with a higher hypoglycemic risk than degludec. This study will assess the efficacy and safety of Continuous Subcutaneous Insulin infusion (CSII) combined with Continuous Glucose Monitoring (CGM), as compared to Multiple Daily Injections (MDI) of insulin analogues, using degludec as basal insulin, associated with traditional self-monitoring of capillary blood glucose (SMBG) in patients with type 1 diabetes. A crossover design was chosen in order to minimize study sample improving statistical power.
Conditions
- Diabetes Mellitus, Type 1
Interventions
CGM+CSIIDevice
Animas Vibe Platinum insulin pump and Dexcom G4 CGM
MDI with degludecDevice
Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Diabetologia AOU Careggi
Florence, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.